Skip to main content
Top
Published in: International Journal of Hematology 6/2014

01-06-2014 | Original Article

Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy

Authors: Arzu Akcay, Zafer Salcioglu, Kazim Oztarhan, Deniz Tugcu, Gonul Aydogan, Nuray Aktay Ayaz, Helen Bornaun, Hulya Sayilan Sen, Ferhan Akici, Burhan Akdana

Published in: International Journal of Hematology | Issue 6/2014

Login to get access

Abstract

The aim of the study is to assess the relationship between T2* magnetic resonance imaging (MRI) values and age, serum ferritin level, left ventricular ejection fraction (LVEF), splenectomy status, and to identify appropriate modifications to chelation therapy based on T2* MRI results of children with thalassaemia major. Sixty-four patients with thalassaemia major (37 girls/27 boys) older than 8 years of age were enrolled in the study. Based on the first T2* MRI, the patients’ myocardial iron depositions were classified into three groups: T2* MRI <10 ms (high risk group), T2* MRI 10–20 ms (medium-risk group) and T2* MRI >20 ms (low-risk group). There was no significant relationship between T2* MRI value and ages, serum ferritin levels and splenectomy status of thalassaemia major patients. The mean LVEFs were 60, 75, and 72.5 % in the high-, medium-, and low-risk groups, respectively (P = 0.006). The mean cardiac iron concentrations calculated from the T2* MRI values were 4.96 ± 1.93, 1.65 ± 0.37, and 0.81 ± 0.27 mg/g in the high-, medium-, and low-risk groups, respectively. Chelation therapies were re-designed in 24 (37.5 %) patients according to cardiac risk as assessed by cardiac T2* MRI. In conclusion, until recently, T2* MRI has been employed to demonstrate cardiac siderosis without a direct relationship with the markers used in follow-up of patients with thalassaemia. However, modifications of chelation therapies could reliably be planned according to severity of iron load displayed by T2* MRI.
Appendix
Available only for authorised users
Literature
2.
go back to reference Borgna-Pignatti C, Rugolotto S, De Stafano P, et al. Survival and complications in patients with transfusion and deferoxamine. Haematologica. 2004;89:1187–93.PubMed Borgna-Pignatti C, Rugolotto S, De Stafano P, et al. Survival and complications in patients with transfusion and deferoxamine. Haematologica. 2004;89:1187–93.PubMed
3.
go back to reference Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006;8:543–7.PubMedCrossRef Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006;8:543–7.PubMedCrossRef
4.
go back to reference Kirk P, Raughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961–8.PubMedCentralPubMedCrossRef Kirk P, Raughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961–8.PubMedCentralPubMedCrossRef
5.
go back to reference Pennel DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann NY Acad Sci. 2005;1054:373–8.CrossRef Pennel DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann NY Acad Sci. 2005;1054:373–8.CrossRef
6.
go back to reference Anderson LJ, Holden S, Davies B, et al. Cardiovascular T-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–9.PubMedCrossRef Anderson LJ, Holden S, Davies B, et al. Cardiovascular T-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–9.PubMedCrossRef
7.
go back to reference Tanner MA, Porter JB, Westwood MA, et al. Myocardial T2* in patients with cardiac failure secondary to iron overload. Blood. 2005;106:406. Tanner MA, Porter JB, Westwood MA, et al. Myocardial T2* in patients with cardiac failure secondary to iron overload. Blood. 2005;106:406.
8.
go back to reference Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18(1):33–9.PubMedCrossRef Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18(1):33–9.PubMedCrossRef
9.
go back to reference Wood JC. Impact of iron assessment by MRI. Hematol Am Soc Hematol Educ Program. 2011;2011:443–50.CrossRef Wood JC. Impact of iron assessment by MRI. Hematol Am Soc Hematol Educ Program. 2011;2011:443–50.CrossRef
12.
go back to reference Modell B, Khan M, Darlison M, et al. Survival in beta-thalassemia major in the UK: data from the UK Thalassemia Register. Lancet. 2000;355:2051–2.PubMedCrossRef Modell B, Khan M, Darlison M, et al. Survival in beta-thalassemia major in the UK: data from the UK Thalassemia Register. Lancet. 2000;355:2051–2.PubMedCrossRef
13.
go back to reference Borgna-Pignatti C, Cappellini MD, De Stafano P, et al. Survival and complications in thalassemia. Ann NY Acad Sci. 2005;1054:40–7.PubMedCrossRef Borgna-Pignatti C, Cappellini MD, De Stafano P, et al. Survival and complications in thalassemia. Ann NY Acad Sci. 2005;1054:40–7.PubMedCrossRef
14.
go back to reference Modell B, Khan M, Darlison M, et al. Improved survival of thalassemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;25:10–42. Modell B, Khan M, Darlison M, et al. Improved survival of thalassemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;25:10–42.
15.
go back to reference Pepe A, Meloni A, Capra M, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96(1):41–7.PubMedCentralPubMedCrossRef Pepe A, Meloni A, Capra M, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96(1):41–7.PubMedCentralPubMedCrossRef
16.
go back to reference Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738–44.PubMedCrossRef Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738–44.PubMedCrossRef
17.
go back to reference Pennell DJ, Porter JB, Capellini DM, et al. Efficacy and safety of Deferasirox (Exjade®) in reducing kardiyac iron in patients with beta-thalassemia major: results from the cardiac substudy of the EPIC trial. Blood. 2008;112:3873. Pennell DJ, Porter JB, Capellini DM, et al. Efficacy and safety of Deferasirox (Exjade®) in reducing kardiyac iron in patients with beta-thalassemia major: results from the cardiac substudy of the EPIC trial. Blood. 2008;112:3873.
18.
go back to reference Aydınok Y, Levent E, Bayraktaroğlu S, et al. Talasemi major olgularında kardiyak demir birikiminin başlangıç yaşı, kardiyak fonksiyonlar, karaciğer demir yoğunluğu ve serum ferritin düzeyleri ile ilişkisi. Ulusal Pediatrik Hematoloji Kongresi, 2009. Aydınok Y, Levent E, Bayraktaroğlu S, et al. Talasemi major olgularında kardiyak demir birikiminin başlangıç yaşı, kardiyak fonksiyonlar, karaciğer demir yoğunluğu ve serum ferritin düzeyleri ile ilişkisi. Ulusal Pediatrik Hematoloji Kongresi, 2009.
19.
20.
go back to reference Kwiatkowski JL. Real-world use iron chelators. Hematol Am Soc Hematol Educ Program. 2011;2011:451–8.CrossRef Kwiatkowski JL. Real-world use iron chelators. Hematol Am Soc Hematol Educ Program. 2011;2011:451–8.CrossRef
21.
go back to reference Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103(5):1934–6.PubMedCrossRef Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103(5):1934–6.PubMedCrossRef
22.
go back to reference Aydinok Y, Bayraktaroglu S, Yildiz D, et al. Myocardial iron loading in patients with thalassemia major in Turkey and the potential role of splenectomy in myocardial siderosis. J Pediatr Hematol Oncol. 2011;33:374–8.PubMedCrossRef Aydinok Y, Bayraktaroglu S, Yildiz D, et al. Myocardial iron loading in patients with thalassemia major in Turkey and the potential role of splenectomy in myocardial siderosis. J Pediatr Hematol Oncol. 2011;33:374–8.PubMedCrossRef
24.
go back to reference Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008;93:741–52.PubMedCrossRef Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008;93:741–52.PubMedCrossRef
25.
go back to reference Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin. 2006;30:239–49.PubMedCrossRef Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin. 2006;30:239–49.PubMedCrossRef
26.
go back to reference Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010;115:2364–71.PubMedCrossRef Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010;115:2364–71.PubMedCrossRef
27.
go back to reference Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica. 2011;96:48–54.PubMedCentralPubMedCrossRef Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica. 2011;96:48–54.PubMedCentralPubMedCrossRef
28.
go back to reference Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012;97:842–8.PubMedCentralPubMedCrossRef Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012;97:842–8.PubMedCentralPubMedCrossRef
29.
go back to reference Wood JC, Thompson AA, Paley C, et al. Deferasirox (Exjade®) monotherapy significantly reduces cardiac iron burden in chronically transfused beta-thalassemia patients: an MRI T2* study. Blood. 2008;112:3882. Wood JC, Thompson AA, Paley C, et al. Deferasirox (Exjade®) monotherapy significantly reduces cardiac iron burden in chronically transfused beta-thalassemia patients: an MRI T2* study. Blood. 2008;112:3882.
30.
go back to reference Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876–84.PubMedCrossRef Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876–84.PubMedCrossRef
31.
go back to reference Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012;120(18):3657–69.PubMedCrossRef Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012;120(18):3657–69.PubMedCrossRef
Metadata
Title
Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy
Authors
Arzu Akcay
Zafer Salcioglu
Kazim Oztarhan
Deniz Tugcu
Gonul Aydogan
Nuray Aktay Ayaz
Helen Bornaun
Hulya Sayilan Sen
Ferhan Akici
Burhan Akdana
Publication date
01-06-2014
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 6/2014
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-014-1575-1

Other articles of this Issue 6/2014

International Journal of Hematology 6/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine